Proxy Biomedical's AlloMEM™ is a freeze-dried, irradiated allograft peritoneal membrane, to be used as a homologous soft tissue wound covering. AlloMEM™ will perform the same basic function in the recipient as in the donor, with membrane replacing membrane. AlloMEM™ is an excellent biological framework, suitable for use in a variety of abdomino-pelvic surgical repair procedures.
Proxy Biomedical was nice enough to take a moment and answer some questions for Surgical Products about its AlloMEM product.
Surgical Products: How was the idea for this product developed? What needs were you looking to meet with this product?
Proxy Biomedical: During general surgery, colorectal, and uro-gynecological procedures entering the abdominal and pelvic areas, the native peritoneum requires dissection, which may already compromised or is entirely absent. Such circumstances lead to loss of anatomical and functional protection between the compromised structure and the adjacent tissues/organs. To recover the anatomical and functional loss, it is proposed that the wound be covered by a biologic (allograft or xenograft) peritoneal membrane. This solution provides the use of anatomically and functionally homologous tissue to replace, recover, and remodel dissected, compromised or absent native peritoneum.
SP: How does this system work?
PB: The extracellular matrix composed of processed peritoneal membrane will support cellular penetration, resorption, and remodeling of surrounding tissue. The peritoneal membrane will be processed to remove immunogenic material (cells, viruses etc.) and will undergo appropriate sterilization. The single layer product will be used as a wound covering during procedures which induce or attempt to repair dissected/compromised/absent peritoneal membrane covering in the abdominal wall and pelvic floor.
SP: What problems does this product address?
PB: Processed peritoneal membrane tissue harvested from human donors provides a necessary anatomically and physiologically similar soft tissue wound covering for addressing pathologies specifically related to the (1) The exposure of surgical wounds within the structures in contact with native peritoneum and (2) Compromised peritoneal membrane as a consequence to a pathology or surgical procedure provides a viable solution. This approach offers a superior solution to the aforementioned pathologies in comparison to: (1) Biodegradable synthetic meshes and (2) Biological membranes harvested from alternative anatomical locations (skin, intestinal submucosa, amniotic membrane, etc.).
SP: How can using this product help facilities improve patient safety, infection rates and overall efficiency?
PB: Allografts have been utilized in an effort to overcome problems associated with synthetic materials as they are homologous in nature. Tissue processing removes cell debris from native peritoneum tissue while retaining the extracellular matrix, providing a biocompatible extracellular scaffold necessary for guided repair of soft tissue. The biologic tissue is resistant to bacterial attachment and it results in a reduced risk of infection compared to synthetics.
For more information, visit www.proxybiomedical.com.